EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins

被引:25
作者
Davies, G. C.
Ryan, P. E.
Rahman, L.
Zajac-Kaye, M.
Lipkowitz, S.
机构
[1] NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA
[2] George Washington Univ, Inst Biomed Sci, Washington, DC USA
[3] NCI, Mol Therapeut Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
EGFRvIII; Cbl proteins; ubiquitin; cancer;
D O I
10.1038/sj.onc.1209662
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The overexpression or mutation of tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR), can lead to the development of cancer. The most common mutation of the EGFR in glioblastomas is the deletion of exons 2-7 known as the EGFRvIII. This mutant receptor cannot bind EGF but, instead, is constitutively active. The Cbl family of ubiquitin ligases (Cbl, Cbl-b, and Cbl-c) targets the activated EGFR for degradation. As the EGFRvIII is transforming, we investigated whether it could be downregulated by the Cbl proteins. The overexpression of all three Cbl proteins resulted in the ubiquitination and degradation of the EGFRvIII. As with the wild-type EGFR, the TK-binding domain and the RING finger of Cbl-b are sufficient for the downregulation of the EGFRvIII. Also, we found that Cbl-b is recruited to the EGFRvIII and inhibits the transformation of NIH 3T3 cells by the EGFRvIII. Mutation of the Cbl-binding site (Y1045F) in the EGFRvIII inhibits its ubiquitination and downregulation by Cbl-b and enhances its ability to transform. Furthermore, the EGFR TK inhibitor, AG 1478, prevents the downregulation of the EGFRvIII by the Cbl proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells expressing this receptor. In conclusion, the EGFRvIII does not transform by escaping regulation by Cbl proteins and this activation-induced downregulation of the EGFRvIII has an important role in mediating the toxicity of anti-EGFRvIII immunotoxins.
引用
收藏
页码:6497 / 6509
页数:13
相关论文
共 50 条
  • [21] Kuan CT, 2000, INT J CANCER, V88, P962, DOI 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO
  • [22] 2-U
  • [23] EGF mutant receptor vIII as a molecular target in cancer therapy
    Kuan, CT
    Wikstrand, CJ
    Bigner, DD
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (02) : 83 - 96
  • [24] Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    Levkowitz, G
    Waterman, H
    Ettenberg, SA
    Katz, M
    Tsygankov, AY
    Alroy, I
    Lavi, S
    Iwai, K
    Reiss, Y
    Ciechanover, A
    Lipkowitz, S
    Yarden, Y
    [J]. MOLECULAR CELL, 1999, 4 (06) : 1029 - 1040
  • [25] The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
    Luwor, RB
    Zhu, HJ
    Walker, F
    Vitali, AA
    Perera, RM
    Burgess, AW
    Scott, AM
    Johns, TG
    [J]. ONCOGENE, 2004, 23 (36) : 6095 - 6104
  • [26] c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms
    Mancini, A
    Koch, A
    Wilms, R
    Tamura, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (17) : 14635 - 14640
  • [27] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
    Mellinghoff, IK
    Wang, MY
    Vivanco, I
    Haas-Kogan, DA
    Zhu, SJ
    Dia, EQ
    Lu, KV
    Yoshimoto, K
    Huang, JHY
    Chute, DJ
    Riggs, BL
    Horvath, S
    Liau, LM
    Cavenee, WK
    Rao, PN
    Beroukhim, R
    Peck, TC
    Lee, JC
    Sellers, WR
    Stokoe, D
    Prados, M
    Cloughesy, TF
    Sawyers, CL
    Mischel, PS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) : 2012 - 2024
  • [28] Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function
    Montgomery, RB
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (02) : 111 - 117
  • [29] MOSCATELLO DK, 1995, CANCER RES, V55, P5536
  • [30] Moscatello DK, 1996, ONCOGENE, V13, P85